title: Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
authors.forename: Feng
authors.initials: F
authors.lastname: Lin
authors.forename: Mark
authors.initials: M
authors.lastname: Drummond
authors.forename: Stephen
authors.initials: S
authors.lastname: O'Brien
authors.forename: Francisco
authors.initials: F
authors.lastname: Cervantes
authors.forename: John
authors.initials: J
authors.lastname: Goldman
authors.forename: Jaspal
authors.initials: J
authors.lastname: Kaeda
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D020732:Cytogenetic Analysis; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D018365:Neoplasm, Residual / Q000175:diagnosis*; D010879:Piperazines / Q000627:therapeutic use*; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000627:therapeutic use*; D012334:RNA, Neoplasm / Q000032:analysis; D012074:Remission Induction / Q000379:methods
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D012334:RNA, Neoplasm; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl